HEMODYNAMIC-EFFECTS INDUCED BY INTRAVENOUS ADMINISTRATION OF HIGH-DOSES OF R-MET HU IL-2 [ALA-125] IN PATIENTS WITH ADVANCED CANCER

被引:7
作者
DIANA, D [1 ]
SCULIER, JP [1 ]
机构
[1] UNIV LIBRE BRUXELLES,CTR TUMEURS,INST JULES BORDET,CLIN HJ TAGNON,INVEST LAB,B-1000 BRUSSELS,BELGIUM
关键词
Cancer; Haemodynamics; Immunotherapy; Interleukin-2; Septic shock;
D O I
10.1007/BF01724796
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
We analyzed the haemodynamic effects of high doses of r-Met Hu IL-2 [ala-125] in four patients with advanced cancer. Haemodynamic parameters were measured daily from days 1 to 6 of treatment. Mean arterial pressure decreased significantly (98±11 mmHg on day 1 versus 84±7 mmHg on day 5;p=0.0435) as did systemic vascular resistance (2042±296 dynes s cm-5 m-2 on day 1 versus 1166±87 dynes s cm-5 m-2 on day 5;p=0.003). There was a significant increase in mean pulmonary artery pressure (13.25±3.30 mmHg on day 1 versus 20.75±7.41 mmHg on day 5;p=0.03), systemic oxygen consumption (173.5±37.8 ml min-1 m-2 on day 1 versus 257.8±20.5 ml min-1 m-2 on day 5;p=0.02) and cardiac index (3.86±0.58 l min-1 m-2 on day 1 versus 5.77±0.21 l min-1 m-2 on day 5;p=0.008). There was no significant decrease in the arteriovenous oxygen content difference (4.5±0.8 ml dl-1 on day 1 versus 4.46±0.22 ml dl-1 on day 5). Increases in oxygen delivery (570±163 ml min-1 m-2 on day 1 versus 750±109 ml min-1 m-2 on day 5 and oxygen extraction ratio (29.95%±6.37% on day 1 versus 34.60%±4.35% on day 5) were not statistically significant. We concluded that the haemodynamic effect induced by high doses of r Hu-IL-2 is similar to that seen in septic shock. © 1990 Springer-Verlag.
引用
收藏
页码:167 / 170
页数:4
相关论文
共 16 条
[1]   INCREASED VASCULAR-PERMEABILITY IN ORGANS MEDIATED BY THE SYSTEMIC ADMINISTRATION OF LYMPHOKINE-ACTIVATED KILLER CELLS AND RECOMBINANT INTERLEUKIN-2 IN MICE [J].
ETTINGHAUSEN, SE ;
PURI, RK ;
ROSENBERG, SA .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1988, 80 (03) :177-188
[2]  
FLETCHER M, 1987, LYMPHOKINE RES, V6, P45
[3]   THE HEMODYNAMIC-EFFECTS OF TREATMENT WITH INTERLEUKIN-2 AND LYMPHOKINE-ACTIVATED KILLER CELLS [J].
GAYNOR, ER ;
VITEK, L ;
STICKLIN, L ;
CREEKMORE, SP ;
FERRARO, ME ;
THOMAS, JX ;
FISHER, SG ;
FISHER, RI .
ANNALS OF INTERNAL MEDICINE, 1988, 109 (12) :953-958
[4]   CARDIOPULMONARY TOXICITY OF ADOPTIVE IMMUNOTHERAPY [J].
GLAUSER, FL ;
DEBLOIS, G ;
BECHARD, D ;
FOWLER, AA ;
MERCHANT, R ;
FAIRMAN, RP .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1988, 296 (06) :406-412
[5]   CARDIOVASCULAR CONSEQUENCES OF RECOMBINANT DNA TECHNOLOGY - INTERLEUKIN-2 [J].
ISNER, JM ;
DIETZ, WA .
ANNALS OF INTERNAL MEDICINE, 1988, 109 (12) :933-935
[6]   THE RAPID INDUCTION BY INTERLEUKIN-2 OF PULMONARY MICROVASCULAR PERMEABILITY [J].
KLAUSNER, JM ;
MOREL, N ;
PATERSON, IS ;
KOBZIK, L ;
VALERI, CR ;
EBERLEIN, TJ ;
SHEPRO, D ;
HECHTMAN, HB .
ANNALS OF SURGERY, 1989, 209 (01) :119-128
[7]   CARDIORESPIRATORY EFFECTS OF IMMUNOTHERAPY WITH INTERLEUKIN-2 [J].
LEE, RE ;
LOTZE, MT ;
SKIBBER, JM ;
TUCKER, E ;
BONOW, RO ;
OGNIBENE, FP ;
CARRASQUILLO, JA ;
SHELHAMER, JH ;
PARRILLO, JE ;
ROSENBERG, SA .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (01) :7-20
[8]   DETECTION OF CIRCULATING TUMOR NECROSIS FACTOR AFTER ENDOTOXIN ADMINISTRATION [J].
MICHIE, HR ;
MANOGUE, KR ;
SPRIGGS, DR ;
REVHAUG, A ;
ODWYER, S ;
DINARELLO, CA ;
CERAMI, A ;
WOLFF, SM ;
WILMORE, DW .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (23) :1481-1486
[9]   INDUCTION OF CIRCULATING TUMOR NECROSIS FACTOR (TNF-ALPHA) AS THE MECHANISM FOR THE FEBRILE RESPONSE TO INTERLEUKIN-2 (IL-2) IN CANCER-PATIENTS [J].
MIER, JW ;
VACHINO, G ;
VANDERMEER, JWM ;
NUMEROF, RP ;
ADAMS, S ;
CANNON, JG ;
BERNHEIM, HA ;
ATKINS, MB ;
PARKINSON, DR ;
DINARELLO, CA .
JOURNAL OF CLINICAL IMMUNOLOGY, 1988, 8 (06) :426-436
[10]   MYOCARDIAL TOXIC EFFECTS DURING RECOMBINANT INTERLEUKIN-2 THERAPY [J].
NORA, R ;
ABRAMS, JS ;
TAIT, NS ;
HIPONIA, DJ ;
SILVERMAN, HJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (01) :59-63